Literature DB >> 32037952

APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis.

Erik S Blomain1, Jeffrey A Rappaport1, Amanda M Pattison1, Babar Bashir1, Ellen Caparosa1, Jonathan Stem1, Adam E Snook1, Scott A Waldman1.   

Abstract

Sporadic colorectal cancer initiates with mutations in APC or its degradation target β-catenin, producing TCF-dependent nuclear transcription driving tumorigenesis. The intestinal epithelial receptor, GUCY2C, with its canonical paracrine hormone guanylin, regulates homeostatic signaling along the crypt-surface axis opposing tumorigenesis. Here, we reveal that expression of the guanylin hormone, but not the GUCY2C receptor, is lost at the earliest stages of transformation in APC-dependent tumors in humans and mice. Hormone loss, which silences GUCY2C signaling, reflects transcriptional repression mediated by mutant APC-β-catenin-TCF programs in the nucleus. These studies support a pathophysiological model of intestinal tumorigenesis in which mutant APC-β-catenin-TCF transcriptional regulation eliminates guanylin expression at tumor initiation, silencing GUCY2C signaling which, in turn, dysregulates intestinal homeostatic mechanisms contributing to tumor progression. They expand the mechanistic paradigm for colorectal cancer from a disease of irreversible mutations in APC and β-catenin to one of guanylin hormone loss whose replacement, and reconstitution of GUCY2C signaling, could prevent tumorigenesis.

Entities:  

Keywords:  GUCA2A; chemoprevention; colorectal cancer; guanylyl cyclase C; transcriptional regulation

Mesh:

Substances:

Year:  2020        PMID: 32037952      PMCID: PMC7515458          DOI: 10.1080/15384047.2020.1721262

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.875


  56 in total

Review 1.  Wnt/β-catenin signaling and disease.

Authors:  Hans Clevers; Roel Nusse
Journal:  Cell       Date:  2012-06-08       Impact factor: 41.582

2.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

Review 3.  APC, signal transduction and genetic instability in colorectal cancer.

Authors:  R Fodde; R Smits; H Clevers
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

4.  The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells.

Authors:  Marc van de Wetering; Elena Sancho; Cornelis Verweij; Wim de Lau; Irma Oving; Adam Hurlstone; Karin van der Horn; Eduard Batlle; Damien Coudreuse; Anna Pavlina Haramis; Menno Tjon-Pon-Fong; Petra Moerer; Maaike van den Born; Gwen Soete; Steven Pals; Martin Eilers; Rene Medema; Hans Clevers
Journal:  Cell       Date:  2002-10-18       Impact factor: 41.582

5.  Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP.

Authors:  K Shailubhai; H H Yu; K Karunanandaa; J Y Wang; S L Eber; Y Wang; N S Joo; H D Kim; B W Miedema; S Z Abbas; S S Boddupalli; M G Currie; L R Forte
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

6.  Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene.

Authors:  Y Miyoshi; H Nagase; H Ando; A Horii; S Ichii; S Nakatsuru; T Aoki; Y Miki; T Mori; Y Nakamura
Journal:  Hum Mol Genet       Date:  1992-07       Impact factor: 6.150

7.  Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine.

Authors:  Peng Li; Jieru E Lin; Inna Chervoneva; Stephanie Schulz; Scott A Waldman; Giovanni M Pitari
Journal:  Am J Pathol       Date:  2007-11-01       Impact factor: 4.307

8.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

Authors:  Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz
Journal:  Cancer Discov       Date:  2012-05       Impact factor: 39.397

9.  Comprehensive molecular characterization of human colon and rectal cancer.

Authors: 
Journal:  Nature       Date:  2012-07-18       Impact factor: 49.962

10.  GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity.

Authors:  Jieru Egeria Lin; Adam Eugene Snook; Peng Li; Brian Arthur Stoecker; Gilbert Won Kim; Michael Sullivan Magee; Alex Vladimir Mejia Garcia; Michael Anthony Valentino; Terry Hyslop; Stephanie Schulz; Scott Arthur Waldman
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

View more
  5 in total

1.  GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer.

Authors:  Amanda N Lisby; John C Flickinger; Babar Bashir; Megan Weindorfer; Sanjna Shelukar; Madison Crutcher; Adam E Snook; Scott A Waldman
Journal:  Expert Rev Precis Med Drug Dev       Date:  2021-02-02

Review 2.  Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.

Authors:  Ariana A Entezari; Adam E Snook; Scott A Waldman
Journal:  Expert Opin Ther Targets       Date:  2021-06-15       Impact factor: 6.797

3.  Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.

Authors:  John C Flickinger; Jeffrey A Rappaport; Joshua R Barton; Trevor R Baybutt; Amanda M Pattison; Adam E Snook; Scott A Waldman
Journal:  Biomark Med       Date:  2021-01-20       Impact factor: 2.851

4.  A β-Catenin-TCF-Sensitive Locus Control Region Mediates GUCY2C Ligand Loss in Colorectal Cancer.

Authors:  Jeffrey A Rappaport; Ariana A Entezari; Adi Caspi; Signe Caksa; Aakash V Jhaveri; Timothy J Stanek; Adam Ertel; Joan Kupper; Paolo M Fortina; Steven B McMahon; James B Jaynes; Adam E Snook; Scott A Waldman
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2021-12-22

5.  Silencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity.

Authors:  Amanda M Pattison; Joshua R Barton; Ariana A Entezari; Alicja Zalewski; Jeff A Rappaport; Adam E Snook; Scott A Waldman
Journal:  Cancer Biol Ther       Date:  2020-06-28       Impact factor: 4.875

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.